Nanovibronix (NASDAQ:FEED) Insider Sells $144,900.00 in Stock

Nanovibronix, Inc. (NASDAQ:FEED) insider Christian Michael Glibert sold 210,000 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $0.69, for a total transaction of $144,900.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Nanovibronix Stock Up 4.2%

FEED stock traded up $0.03 during midday trading on Monday, hitting $0.70. The company’s stock had a trading volume of 398,578 shares, compared to its average volume of 7,079,931. The company has a market cap of $4.26 million, a price-to-earnings ratio of -0.08 and a beta of 1.52. Nanovibronix, Inc. has a 52-week low of $0.63 and a 52-week high of $17.40. The firm has a 50-day moving average of $1.12.

Nanovibronix (NASDAQ:FEED) last released its earnings results on Monday, May 18th. The company reported ($6.88) EPS for the quarter. Nanovibronix had a negative return on equity of 54.25% and a negative net margin of 923.20%.The company had revenue of $0.65 million for the quarter.

Analyst Ratings Changes

A number of equities analysts recently commented on FEED shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Nanovibronix in a research note on Friday, April 24th. Wall Street Zen upgraded shares of Nanovibronix from a “strong sell” rating to a “sell” rating in a research note on Tuesday, April 28th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Nanovibronix has a consensus rating of “Sell”.

About Nanovibronix

Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company’s product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies.